RGS Genome is a drug discovery company focusing on epilepsy, schizophrenia and other neurological diseases.

History:

RGS Genome was purchased by Xenon Biosearch (which is now known asXenon Pharmaceuticals. It was spun back out as Emerillon Therapeutics in 2003.

Employment

Email:

Fax:

Mail:

General Info:

Ticker:

Employees:

Regions:
North America

Research Focus:
Disease Therapeutics-Research

 

Profiles:

 

News:

Keywords: 

Strategic Partnerships: